<DOC>
	<DOC>NCT00120380</DOC>
	<brief_summary>The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist bosentan.</brief_summary>
	<brief_title>Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>IPAH &gt; 3 months treatment with bosentan 6 minute walk distance 150 425 m other forms of pulmonary hypertension severe comorbidities cotreatment with sildenafil or investigational drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Idiopathic pulmonary arterial hypertension</keyword>
</DOC>